Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Wallace

Deputy Editor

Having previously worked in the European chemicals industry, Dave has now spent almost a decade with Generics bulletin. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Advertisement
Set Alert for Articles By David Wallace

Latest From David Wallace

AESGP Supports European Commission On Environment

European self-medication association AESGP is one of several European pharmaceutical industry bodies to have lent their backing to the latest European Commission strategic approach to pharmaceuticals in the environment.
Europe Regulation

Alvogen Fails In Revlimid IPR Attempt

Alvogen’s inter partes review petition challenging a Revlimid patent in the US has been denied by the PTAB, following similar denials of petitions by Dr Reddy’s over three other Revlimid patents.

Intellectual Property United States

UK’s CMA Will Not Take Action Over Remicade Discount Scheme

The UK’s competition regulator will not take action against MSD over a suspected anti-competitive discount scheme for Remicade (infliximab), despite an earlier provisional finding that MSD had a dominant market position and the scheme was in breach of competition law.

Legal Issues Biosimilars

Canadian Body Welcomes Pharmacare Report

An interim report on implementing national pharmacare in Canada that highlights the importance of cost savings and access to medicines has been welcomed by local off-patent industry body the CGPA.

Market Intelligence Canada

Industry Alliance Supports Commission On Environment

Off-patent industry association Medicines for Europe is one of several European pharmaceutical associations to have lent their backing to the latest European Commission strategic approach to pharmaceuticals in the environment.

Regulation Europe

Australia’s GBMA Aims To Educate With ‘Biosimilar Week’

Australia’s GBMA industry association will seek to promote biosimilars through a dedicated ‘Biosimilar Week’ in late April and early May this year, running as part of a three-year education program being pursued by the association and industry stakeholders.

Biosimilars Australia
See All
Advertisement
UsernamePublicRestriction

Register